Novasep opened a new, €11 million (approximately $11.6 million) bioconjugation facility for antibody drug conjugates (ADCs) at its Le Mans site in France. The 2000-m2 purpose-built facility comprises two GMP production suites for clinical- and commercial-scale production of ADCs and offers R&D services, together with QC and scaleup laboratories. Novasep already has manufacturing platforms for producing the ADC payloads, linkers, and monoclonal antibodies.
“We designed the facility to ensure smooth and robust scaleups and address the ADC-specific analytical and process challenges,” commented Rachel de Luca, general manager of the Le Mans site. “Our team has a long experience in applying DoE to chemical synthesis and bioprocessing and efficiently develop conjugation and purification steps on a wide range of ADC platforms.”
Based in Lyon, France, Novasep provides process development, contract manufacturing, and purification services for small-molecule active pharmaceutical ingredients (APIs), intermediates, and biomolecules. Within the last 10 days, the firm announced it was investing €27 million (approximately 28.5 million) to build a new viral vector production facility at its site in Seneffe, Belgium. The new facility will complement existing laboratory-scale suites at Novasep's neighboring Gosselies facility.
In Decmeber, Novasep sold its U.S. subsidiary TangenX Technology to Repligen for $39 million. TangenX develops tangential flow filtration technologies for or purification of biopharmaceuticals.